Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039177 · ClinicalTrials.gov registry record · Phase 1
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
A Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Erasca.
- Active
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
- 14
- Study locations
NCT05039177: Active Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Erasca.
NCT05039177 is a Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Erasca. The registered enrollment target is 102 participants, below the 184-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (45% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05039177, a Phase 1 study of Metastatic Colorectal Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Erasca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
- 14
- Study locations
Study Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
Primary Outcome
Based on adverse events observed during dose escalation
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Palbociclib
- DRUG Encorafenib
- DRUG ERAS-007
Study Locations (14)
California
- City of Hope - Duarte
- University of California Irvine College of Medicine - Orange
- UCSF Mount Zion Medical Ctr - San Francisco
Alabama
- University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) - Birmingham
Maryland
- The Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Cancer Institute - Detroit
Missouri
- Washington University (Siteman Cancer Center) - St Louis
North Carolina
- Duke Cancer Institute - Durham
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05039177 still lists
NCT05039177 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 184-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.
NCT05039177 lists 14 locations in 12 states (California, Alabama, Maryland).
Frequently Asked Questions
What is clinical trial NCT05039177 about?
NCT05039177 is a clinical study titled "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies". * To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other ca...
What is the current status of trial NCT05039177?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2021-09-20. Estimated completion is 2025-12.
What conditions does trial NCT05039177 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05039177?
The interventions under investigation include: Cetuximab (DRUG), Palbociclib (DRUG), Encorafenib (DRUG), ERAS-007 (DRUG).
Who is sponsoring clinical trial NCT05039177?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039177 being conducted?
This trial has 14 study locations across Alabama, California, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05039177's enrollment target sits among peer trials
102 23rd of 45 higher than 23 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI